How could ultraslow low-dose thrombolytic infusion regimes affect high thrombosis resolution rates in prosthetic valve thrombosis?

The development of lower dose, slower infusion protocols, notably using Alteplase without bolus, has dramatically improved outcomes. Clinical trials show comparable or superior thrombosis resolution rates with ultraslow infusion versus rapid infusion or surgery, but with markedly reduced complication rates. Mechanistically, ultraslow infusion may help to localize fibrinolysis to the thrombus site, minimizing systemic fibrinogen depletion and hemorrhagic risk. Ultraslow (25 hours) low-dose (25 mg) thrombolysis with Alteplase is a safe and effective first-line therapy for PVT patients, achieving high success in clot resolution while limiting bleeding and embolic complications. Ongoing evidence and mechanistic rationale suggest that, in the absence of contraindications, this strategy can often be preferable to traditional rapid high-dose thrombolysis or emergency surgery.